Volume 5, Number 43
Monday, October 31, 2005



In this issue: (click heading to view article)
Dietary n-3 and n-6 Fatty Acids and Dry Eye Syndrome in Women
CCT Heritability: The Twin Eye Studies
Cohesive Tensile Strength of Human LASIK Wounds
Briefly











Dietary n-3 and n-6 Fatty Acids and Dry Eye Syndrome in Women

Boston’s Brigham and Women’s Hospital, the Schepens Eye Research Institute, the Massachusetts Eye and Ear Infirmary and Harvard Medical School conducted a study aimed at determining the association between the dietary intake and ratio of n-3 and n-6 fatty acids and dry eye syndrome occurrence in women.

The cross-sectional study included 32,470 women aged 45 to 84 years old who provided information on diet and dry eye syndrome, drawn from 39,876 female health professionals in the Women’s Health Study (WHS). Researchers assessed fatty acid intakes using a validated food-frequency questionnaire and assessed dry eye syndrome using self-reports of clinically diagnosed cases. Of the sample, 1,546 subjects (4.7 percent) reported dry eye syndrome. Researchers used logistic regression models to estimate the odds ratios and 95 percent confidence intervals to describe the relation of fatty acid intake with dry eye syndrome.

After adjustments for demographic factors, hormone therapy and total fat intake, the odds ratio for the highest vs. the lowest quintile of n-3 fatty acids was 0.83. A higher ratio of n-6 to n-3 fatty acid consumption was associated with a significantly increased risk of dry eye syndrome for greater than 15 to 1 vs. less than 4 to 1. In addition, tuna consumption (one serving = 113 g or 4 oz.) was inversely associated with dry eye syndrome. The results suggest that a higher dietary intake of n-3 fatty acids is associated with a decreased incidence of dry eye syndrome in women. The findings are consistent with anecdotal clinical observations and postulated biological mechanisms.

SOURCE: Miljanovi B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Amer J Clin Nutr 2005;82(4):887-93.
Table of Contents











CCT Heritability: The Twin Eye Studies

Australian researchers conducted a classic twin study to determine the heritability of central corneal thickness (CCT), an important parameter in glaucoma assessment.

Investigators compared the concordance of CCT between monozygotic (MZ) and dizygotic (DZ) twins. A total of 256 twin pairs (131 MZ and 125 DZ) were recruited from three centers: the Twin Eye Study in Tasmania, the Brisbane Adolescent Twin Study and the Twins U.K. Adult Registry held at St. Thomas" Hospital in London, England. The mean age of subjects was 38 years (range, 8 to 81). As part of an extensive ophthalmic evaluation, researchers measured CCT by ultrasound pachymetry. They used structural equation modeling with the Mx program (Department of Psychiatry, Medical College of Virginia, Richmond, VA) to determine the heritability of CCT.

The mean CCT of all eyes examined was 544.5 +/- 37.3 microns. The CCT measurements correlated more highly in MZ twins than in DZ twins, with intraclass correlation coefficients of 0.95 and 0.52, respectively, suggesting a strong genetic influence. A model of additive genetic and unique environmental effects provided the best fit, yielding a heritability of 0.95 (95 percent confidence interval, 0.93 to 0.96) with the remaining variation being attributable to unique environmental factors.

SOURCE: Toh T, Liew SH, Mackinnon JR, et al. Central corneal thickness is highly heritable: the twin eye studies. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3718-22.
Table of Contents

 










Cohesive Tensile Strength of Human LASIK Wounds

Atlanta’s Emory University conducted a study to measure the cohesive tensile strength of human LASIK corneal wounds. Investigators cut 25 human eye bank corneas from 13 donors that had LASIK into 4-mm corneoscleral strips. They dissected them to expose the interface wound. Using a motorized pulling device, they recorded the force required to separate the wound. Intact and separated specimens were processed for light and electron microscopy. Five normal human eye bank corneas from five donors served as controls. A retrospective clinical study was performed on 144 eyes that had LASIK flap-lift retreatments, providing clinical correlation.

The mean tensile strength of the central and paracentral LASIK wounds showed minimal change in strength over time after surgery, averaging 2.4 percent (0.72 +/- 0.33 g/mm) of controls (30.06 +/- 2.93 g/mm). In contrast, the mean peak tensile strength of the flap wound margin gradually increased over time after surgery, reaching maximum values by 3.5 years when the average was 28.1 percent (8.46 +/- 4.56 g/mm) of controls. Histologic and ultrastructural correlative studies showed that the plane of separation always occurred in the lamellar wound, which consisted of a hypocellular primitive stromal scar centrally and paracentrally and a hypercellular fibrotic stromal scar at the flap wound margin. The pathologic correlations demonstrated that the strongest wound margin scars had no epithelial cell ingrowth--the strongest typically being wider or more peripherally located. In contrast, the weakest wound margin scars had epithelial cell ingrowth. The clinical series demonstrated the ability to lift LASIK flaps without complications during retreatments up to 8.4 years after initial surgery, correlating well with the laboratory results.

The authors of the study concluded that the human corneal stroma typically heals after LASIK in a limited and incomplete fashion, which results in a weak, central and paracentral hypocellular primitive stromal scar that averages 2.4 percent as strong as normal corneal stroma. Conversely, the LASIK flap wound margin heals by producing a tenfold stronger, peripheral hypercellular fibrotic stromal scar that averages 28.1 percent as strong as normal corneal stroma but displays marked variability.

SOURCE: Schmack I, Dawson DG, McCarey BE, et al. Cohesive tensile strength of human LASIK wounds with histologic, ultrastructural, and clinical correlations. J Refract Surg. 2005 Sep-Oct;21(5):433-45.
Table of Contents





BRIEFLY
  • SIRNA THERAPEUTICS ANNOUNCES UPDATED PHASE I CLINICAL TRIAL DATA FOR siRNA MOLECULE. Sirna Therapeutics, Inc. has announced updated interim data on its Phase I trial for AMD. The data shows that Sirna’s short interfering RNA (siRNA) molecule, Sirna-027, which targets vascular endothelial growth factor receptor-1 (VEGFR-1), is safe and well tolerated with no dose limiting toxicities observed. One hundred percent of 22 patients showed visual acuity stabilization, and 23 percent experienced clinically significant improvement in visual acuity after eight weeks from a single injection. The results also show the continued demonstration of biological activity in humans of a synthetic siRNA, as shown by a relevant decrease in central foveal thickness measured by ocular coherence tomography. This data applies to patients in the 100, 200, 400, 800 and 1200 microgram cohorts; the remaining 1600 microgram cohort is scheduled to be completed shortly. After the Phase I trial is complete, Allergan will assume all developmental responsibilities for Sirna-027, according to a strategic alliance between Sirna and Allergan. The two companies anticipate that Sirna-027 will advance to Phase II trials in 2006.
  • CLINICAL TRIALS BEGIN FOR IOP-LOWERING DEVICE WITHOUT BLEB. The FDA has granted an Investigational Device Exemption (IDE) approval to SOLX, Inc. to begin studies of the DeepLight Gold Micro-Shunt (GMS) implant for glaucoma. The GMS is a 24-karat gold, ultra-thin, flat plate designed for implantation through a single micro-incision. It contains micro-tubular channels that bridge the anterior chamber and suprachoroidal space, maximizing uveoscleral outflow to reduce IOP. The GMS rests permanently in the suprachoroidal space and cannot be felt by the patient. It is biocompatible and physically inert, and it has been shown to eliminate the formation of scar tissue. Multicenter studies of 70 eyes with up to two years follow-up in Spain and Israel demonstrated excellent clinical results. The randomized, multicenter study will evaluate safety and efficacy of the GMS for lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma. who have failed maximum medical therapy and at least one surgical intervention.
  • NPS PHARMACEUTICALS TO PROMOTE RESTASIS TO U.S. RHEUMATOLOGISTS. NPS Pharmaceuticals, Inc. has forged an agreement with Allergan to promote Restasis (cyclosporine ophthalmic emulsion 0.05% to rheumatologists for their patients with autoimmune disorders. Under the agreement, Allergan will supply product, promotional materials, training and other support to NPS rheumatology sales professionals, who will promote Restasis exclusively to U.S. rheumatologists for four years starting November 2005. Allergan will continue to promote Restasis to ophthalmologists and optometrists through its sales force and direct-to-consumer advertising; NPS will support Allergan"s promotional efforts through sales and marketing activities directed to rheumatologists.
  • INCREASE IN ACANTHAMOEBA KERATITIS NOTED. Ophthalmologists at Wills Eye Hospital, Philadelphia, have reported a recent dramatic increase in cases of Acanthamoeba keratitis. The infection was detected in 19 patients between January 2004 and August 2005, according to Fabiano N. Rocha, MD. All 19 patients had a history of frequent-replacement contact lens wear and were using multipurpose solutions for lens care. Forty-two percent had a history of exposure to well water; 26 percent reported swimming without removing their lenses. At the time of presentation, nearly three-fourths of the patients had been misdiagnosed with herpes simplex virus keratitis and had received steroids. Upon diagnosis of Acanthamoeba keratitis, all of the patients received combined therapy with topical antiamoebic drugs. Of the nine patients who completed their antiamoebic therapy, best corrected visual acuity was 20/30 or better in seven and count fingers to hand motion in the other two. Overall, visual outcomes were better in patients who presented with epithelial radial keratitis compared with those who had a ring ulcer or stromal disease at the time of presentation.


Table of Contents




 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
It"s only been up and running a few short weeks. Yet, it"s already clear that the Check Yearly. See Clearly.(SM) marketing campaign is opening consumers" eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.